Regular ArticleSecond-generation interferons for cancer: clinical targets
References (202)
- et al.
Human interferon omega binds to the alpha/beta receptor
J Bill Chem
(1991) - et al.
Unique features of the trophoblast interferons
Pharmacol Ther
(1991) - et al.
Interferon alpha 2-b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration
Blood
(1988) - et al.
Prolonged subcutaneous administration of recombinant α 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583
Blood
(1993) - et al.
Response at three months is a good predicitive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha
Blood
(1998) - et al.
A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
Blood
(1995) - et al.
UK Medical Research council randomized, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research council’s Working Parties for Therapeutic Trials in Adult Leukaemia
Lancet
(1995) - et al.
An evidence based analysis of the effect of busulfan, hydroxyures, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology
Blood
(1999) - et al.
Interferon-alpha2c and LD ara-c for the treatment of patients with CML: results of the Austrian multi-center phase II study
Leuk Res
(1997) - et al.
Interferon-alpha restors normal beta-1 integrin-mediated inhibition of hematoppesic prohibitor proliferation by the marrow microenvironment in chronic myelogoneous leukemia
Blood
(1996)
Fas mediated modulation of ber/abl in chronic myelogenous leukemia results in differntial effects on poptosis
Blood
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias
Blood
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis
Lancet
High-dose intravenous melphalan for plasma cell leukemia and myeloma
Lancet
Interferon therapy in myelomatosis
Lancet
Natural interferon-alpha in combination with melphalan/prednisolone versus melphalan/prednisolone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden
Blood
Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicentre randomized trials and summary of other studies
Ann Oncol
Recombinant interferon alpha-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: A prospective randomized trial
Eur J Cancer Clin Oncol
Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon
Cell Immunol
Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma
Blood
A collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma
Am J Med
A long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
New Engl J Med
The structure of one of the eight or more distinct chromsomal genes for human interferon α
Nature
The structure of eight distinct cloned human leukocyte interferon cDNAs
Nature
Structure of the human immune interferon gene
Nature
The human interferon-alpha species and hydrid proteins
Sem Oncol
Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans
J Clin Oncol
Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha interferons differing in antiviral activity
Cancer Res
Research and development of recombinant interferon −α 1b
J Interferon Cytokine Res
A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities
J Interferon Res
Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes
Int J Cancer
Differential effects of recombinant human leukocyte interferons on cell surface antigen expression
Cancer Res
The classification and biological functions of the interferons. A review
J hepatol
Phase I Study of Polyethylene Glycol (PEG) Interferon Alpha-2b in Patients with Solid Tumors
Proc Am Soc Clin Oncol
Enhancement of interferon-beta activity by complex formation with the soluble IFNAR-2 interferon receptor subunit
J. Ifn Cytokine Res
Variation in the binding of 125I-labeled interferon-bser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro
Cancer Res
Initial interaction of human fibroblast and leukocyte interferons with FS-4 fibroblasts
J Gen Virol
Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells
J Immunol
Cytotoxicity of human beta interferon for differentiating leukemic HL-60 cells
Cancer Res
Radiosensitization of human bronchogenic carcinoma cells by interferon beta
J Interferon Res
The comparative antiproliferative activity in vitro of natural interferons α and β for diploid and transformed human cells
Cancer Res
Synergistic antiproliferative effects of human recombinant α 54 or β ser with g interferon on human cell lines of various histogenesis
Cancer Res
Antiproliferative effects of interferons on human melanoma cells in the human tumor colony forming assay
J Interferon Res
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays
Proc Natl Acad Sci USA
Evolution of a cytokine using DNA family shuffling
Nature Biotechnol
Divergence of binding, signaling, and biological responses to recombinant human hybrid
IFN J Immunol
Treatment of chronic myelogenous leukemia: curent status and investigational options
Blood
Recombinant IFN-alpha therapy of chromosome-negative myeloproliferative disorders with thrombocytosis
Am J Med
Interferon-alpha treatment of six patients with the idiopathic hyperepsinophilic syndrome
Ann Intern Med
Cited by (75)
IFNs, ISGylation and cancer: Cui prodest?
2012, Cytokine and Growth Factor ReviewsCitation Excerpt :Secreted ISG15 can act as a cytokine, stimulating IFN type II production from CD3 + T cells [60] or as chemotactic factor for neutrophils [61]. IFNs treatment, alone or in combination with standard therapies has been used against many cancer types [62]. In certain cases type I IFNs are still in use whereas, in others, they have been replaced by new more efficient therapies.
Investigation on interferon alpha-inducible protein 6 (IFI6) gene as a candidate for meat and carcass quality in pig
2011, Meat ScienceCitation Excerpt :IFI6 is not mapped yet in pig but the human IFI6 gene locates on HSAP1p35 which is homologous to a chromosomal region on the SSC6 where several QTL for meat quality traits (meat colour, water content, drip loss and pH, muscling and carcass length) have been mapped (Markljung et al., 2008; Taniguchi et al., 2010; Edwards et al., 2008). IFI6 is reported to have anti-apoptotic and immunomodulatory effects (Tahara et al., 2005; Urabe, 1994; Borden, Lindner, Dreicer, Hussein, & Peereboom, 2000; Schaar et al., 2005). Genes involved in apoptotic pathways were found to be down regulated in high drip loss animals (Ponsuksili et al., 2008).
Interleukin-7 treatment counteracts IFN-α therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques
2010, BloodCitation Excerpt :Over the last decade, immunotherapy has become increasingly important in the treatment of human pathologies. IFN-α–based therapy was the first and remains one of the most used treatments for viral infections, such as hepatitis C33 as well as an immunomodulating compound for stimulation of specific immunity in advanced cancers.34-37 Despite its efficacy, IFN-α treatment is always associated with significant side effects.
Cytokine-induced tumor suppressors: A GRIM story
2010, CytokineInfluence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein
2010, BiochimieCitation Excerpt :Later, other important functions of these cytokines were discovered, including potent antiproliferative and immunomodulatory effects [2]. Recombinant hIFN-α2 derived from genetically engineered Escherichia coli represents the cytokine exhibiting the longest record of use in clinical oncology, including treatment of hematological malignancies (hairy cell leukemia, chronic myeloid leukemia and some B- and T-cell lymphomas) and certain solid tumors (melanoma, renal carcinoma and Kaposi’s sarcoma) [3,4]. Also, because of its antiviral properties, rhIFN-α is the treatment of choice for patients with chronic hepatitis B and C virus infections [5,6].
Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate
2010, Journal of Biotechnology
- 1
Email: [email protected]